NOX-6-18 is a highly potent and selective GPR132 antagonist that promotes insulin secretory activity, regulates macrophage reprogramming in pancreatic islets, and reduces weight gain, and may be used as a candidate ingredient for the treatment of diabetes.
NOX-6-18 (GPR132 antagonist 1) is a potent, selective GPR132 antagonist with IC50 of 17 nM. It modulates macrophage reprogramming within pancreatic islets, decreases weight gain, and enhances glucose metabolism in mice fed a high-fat diet.
